Candidates include Medis, an Iceland-based firm that develops generics for other companies, and some of its respiratory assets.
Medis could fetch $500M - $1B while the respiratory business could be valued as high as $2B, depending on which treatments are included and the value given to the pipeline.
The company aims to cut its business-choking level of debt which totaled ~$35B at the end of June.
Now read: Teva Pharmaceuticals - A Deal Too Far? »
Subscribe for full text news in your inbox